Clinical trial
A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis
NCT00046072 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00046072 |
|---|---|
| Title | A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis |
| Official title | A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection |
| Intervention type | Drug |
| Interventions | E5564 |
| Enrollment | 300 |
| Start date | Oct 1, 2001 |
| Completion | Apr 1, 2005 |
| First posted | Sep 20, 2002 |
| Last update posted | Dec 12, 2005 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: